StreetInsider.com News Articles

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening

Thu, 30 Jul 2026 12:02:00 -0400

Both entities have signed a global strategic commercial agreement.
The agreement marks an important new step in the execution of Median’s partnership-driven commercialization strategy for eyonis® LCS
The agreement builds on the successful regulatory milestones achieved by eyonis® LCS with FDA 510(k) clearance in February 2026 and CE marking in July 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio

Wed, 22 Jul 2026 12:05:00 -0400

Strengthened cash position at €60.8 million as of June 30, 2026, reflecting the successful €50 million capital increase completed in June 2026.
Cash runway through the first half of 2028, with a potential extension into the first half of 2029 upon exercise of warrants issued in 2025.
First-half 2026 iCRO revenue of €11.8 million, up 4.4% from €11.3 million in the first half of 2025.
Record iCRO order backlog of €82.4 million as of June 30, 2026 (+15.6% vs. H1 2025), providing strong visibility into future revenue growth.
eyonis® LCS has received FDA clearance and CE marking.
Accelerated commercial rollout of eyonis® LCS in

Half Year Median Technologies Liquidity Contract Statement

Wed, 15 Jul 2026 11:45:00 -0400

First half of 2026

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of June 30, 2026:

37,900 shares
€184,342.20 in cash.

Transactions during the first half of 2026:

BUY

257,824 shares

€1,243,768.89